TOKAI (9729) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
7 Aug, 2025Executive summary
Net sales rose 11.3% year-over-year to ¥39,182 million for the quarter ended June 30, 2025, marking the fifth consecutive annual increase.
Operating profit increased 16.1% year-over-year to ¥1,871 million, reaching a record high.
Profit attributable to owners of parent declined 21.7% year-over-year to ¥1,345 million.
Comprehensive income improved to ¥1,570 million from ¥1,399 million year-over-year.
Equity ratio improved to 75.2% from 74.8% sequentially.
Financial highlights
Gross profit grew to ¥9,108 million from ¥8,236 million year-over-year.
Ordinary profit increased 12.3% to ¥2,050 million.
Basic earnings per share fell to ¥39.79 from ¥49.52 year-over-year.
Total assets increased to ¥114,045 million; net assets rose to ¥86,458 million.
Capital investments totaled ¥1,155 million, up 1.3% year-over-year.
Outlook and guidance
Full-year net sales forecast at ¥157,976 million, up 5.6% year-over-year.
Operating profit forecast at ¥8,216 million, nearly flat year-over-year.
Profit attributable to owners of parent projected to rise 16.2% to ¥5,499 million.
Annual dividend forecast raised to ¥68.00 per share.
Forecasts are subject to risks and uncertainties, and actual results may differ.
Latest events from TOKAI
- Record sales and profit growth, driven by rental, pharmacy, M&A, and special dividends.9729
Q3 202612 Feb 2026 - Record sales and profit growth, higher dividends, and capital returns planned.9729
Q2 202611 Nov 2025 - Net sales and net income increased, but full-year profit is forecast to decline.9729
Q2 202513 Jun 2025 - Sales and profits rose, with strong Q1 gains and stable full-year outlook.9729
Q1 202513 Jun 2025 - Record sales and profit growth, but net income fell on impairments; outlook remains positive.9729
Q4 20256 Jun 2025 - Record sales growth, but profit pressured by higher costs and securities losses.9729
Q3 20255 Jun 2025